Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. News
  7. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-12-01
77.70 CNY   -2.88%
12/02WuXi STA and Multiply Labs announce partnership and successfully deploy robotic manufacturing system for personalized drugs
AQ
11/27WuXi AppTec Shares Dive on Shareholders' Plan to Pare Stake
DJ
11/23WuXi AppTec Begins Construction of Wuxi STA Pharmaceutical East China R&D Facility
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wuxi Biologics, Peers Slump After Biden Signs Order to Boost U.S. Biotech Industry

09/12/2022 | 11:24pm EST

By Clarence Leong


Shares of Wuxi Biologics (Cayman) Inc. and its peers fell in Tuesday morning trade in Hong Kong, after the Biden administration's move to bolster the U.S. biotechnology industry stoked fears of Chinese companies being targeted.

Wuxi Biologics slid 17% to 55.05 Hong Kong dollars (US$7.01), heading toward its biggest one-day percentage drop since February. The stock has lost 41% so far this year.

Other pharmaceutical companies also declined, with Wuxi AppTec Co., Pharmaron Beijing Co. and Asymchem Laboratories (TianJin) Co. down between 10% and 13%. The city's benchmark Hang Seng Index was up 0.2%.

The selloff came after President Biden on Monday signed an executive order to advance biotechnology and biomanufacturing innovation domestically, which includes developing a strategy to "mitigate risks posed by foreign adversary involvement in the biomanufacturing supply chain," according to a White House statement.

The Covid-19 pandemic has shown the "vital role of biotechnology and biomanufacturing" in developing life-saving vaccines, the statement said.

The Chinese biomanufacturing sector's "fast-growing profile and efficiency in the Covid-19 context puts the sector under spotlight," Nomura analysts Jialin Zhang and John Nie said in a note. They said they expect short-term pressure on the sector and in particular Wuxi Biologics.

In early July, media reports suggested that Wuxi Biologics may be closer to being removed from a U.S. trade list, boosting the stock. Two units of Wuxi Biologics were placed on an "unverified list" by the Commerce Department in February, subjecting them to tighter export controls.


Write to Clarence Leong at clarence.leong@wsj.com


(END) Dow Jones Newswires

09-12-22 2323ET

Stocks mentioned in the article
ChangeLast1st jan.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. -3.11% 133.21 End-of-day quote.-57.13%
NOMURA CO., LTD. -1.01% 985 Delayed Quote.4.20%
NOMURA CORPORATION 2.09% 1076 Delayed Quote.20.32%
PHARMARON BEIJING CO., LTD. -2.43% 65.01 End-of-day quote.-30.97%
WUXI APPTEC CO., LTD. -2.88% 77.7 End-of-day quote.-34.47%
WUXI BIOLOGICS (CAYMAN) INC. 2.27% 51.8 Delayed Quote.-44.03%
All news about WUXI APPTEC CO., LTD.
12/02WuXi STA and Multiply Labs announce partnership and successfully deploy robotic manufac..
AQ
11/27WuXi AppTec Shares Dive on Shareholders' Plan to Pare Stake
DJ
11/23WuXi AppTec Begins Construction of Wuxi STA Pharmaceutical East China R&D Facility
CI
10/27WuXi AppTec Reports Profit Surge in Q3
MT
10/27Wuxi Apptec Terminates Hong Kong Share Sale Proposal; Shares Climb 7%
MT
10/27Nomura Adjusts Wuxi Apptec's Price Target to HK$136.97 From HK$171.11, Keeps at Buy
MT
10/27Nomura Adjusts Wuxi Apptec's Price Target to 138.58 Yuan From 147.15 Yuan, Keeps at Buy
MT
10/26WuXi AppTec's Shares Rise Following Strong Third-Quarter Earnings
DJ
10/26WuXi AppTec Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, ..
CI
10/26Wuxi Apptec : 2022 Third Quarterly Results Presentation
PU
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Financials
Sales 2022 39 066 M 5 565 M 5 565 M
Net income 2022 9 085 M 1 294 M 1 294 M
Net cash 2022 1 314 M 187 M 187 M
P/E ratio 2022 25,5x
Yield 2022 0,86%
Capitalization 226 B 32 173 M 32 173 M
EV / Sales 2022 5,75x
EV / Sales 2023 4,92x
Nbr of Employees 45 646
Free-Float 65,5%
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 77,70 CNY
Average target price 132,75 CNY
Spread / Average Target 70,8%
EPS Revisions
Managers and Directors
Min Zhang Chen Co-Chief Executive Officer & Executive Director
Qing Yang Co-CEO, Executive Director & Executive VP
Ge Li Chairman & President
Ellis Chu Co-Chief Financial Officer & Senior Vice President
Ming Shi Co-Chief Financial Officer
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.-34.47%32 173
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.20.54%81 852
BIONTECH SE-34.16%41 250
GENMAB A/S24.60%30 178
ARGENX SE22.14%22 340